Aikido Pharma Inc Revenue Growth Rates (DOMH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aikido Pharma Inc  (NASDAQ: DOMH)
    Sector • Financial    Industry • Investment Services
   Industry • Investment Services
   Sector • Financial
 

DOMH's Revenue Growth by Quarter and Year

Aikido Pharma Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DOMH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 16.79
1st Quarter March 35.81
FY 52.60





DOMH Revenue second quarter 2026 Y/Y Growth Comment
Aikido Pharma Inc reported drop in Revenue in the second quarter 2026 by -56.85% to $ 16.79 millions, from the same quarter in 2025.
The fall in the second quarter 2026 Aikido Pharma Inc's Revenue compares unfavorably to the Company's average Revenue doubling of 295.91%.

Looking into second quarter 2026 results within Investment Services industry 2 other companies have achieved higher Revenue growth. While Aikido Pharma Inc' s Revenue meltdown of -56.85% ranks overall at the positon no. 146 in the second quarter 2026.


DOMH Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 358.08 % 549.5 % -
3rd Quarter September - 1157.92 % 320.83 % -
2nd Quarter June -56.85 % 530.63 % 8714.29 % -
1st Quarter March 394.61 % 428.47 % - -
FY   - 600.22 % 789.22 % -

Financial Statements
Aikido Pharma Inc's second quarter 2026 Revenue $ 16.79 millions DOMH's Income Statement
Aikido Pharma Inc's second quarter 2025 Revenue $ 38.91 millions Quarterly DOMH's Income Statement


DOMH Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -40.87 % 62.38 % 5.21 %
3rd Quarter September - 30.61 % -34.52 % 1271.43 %
2nd Quarter June -53.12 % 437.43 % 350.36 % -
1st Quarter March 19.17 % 10.37 % 35.64 % -
FY (Year on Year)   - 600.22 % 789.22 % -


Back to DOMH Growth rate Comparisons >> Back to DOMH Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Investment Services Industry #3
Financial Sector #16
Overall #146

Revenue Y/Y Growth Statistics
High Average Low
691.09 % 295.91 % -68.3 %
(Sep 30 2025)   (Mar 31 2015)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Investment Services Industry #3
Financial Sector #16
Overall #146
Revenue Y/Y Growth Statistics
High Average Low
691.09 % 295.91 % -68.3 %
(Sep 30 2025)   (Mar 31 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aikido Pharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1256.34 % 87.8 % -100 %
(Sep 30 2023)  


DOMH's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Aikido Pharma Inc disclosed fall in Revenue from the first quarter by -53.12% to $ 16.79 millions, from $ 35.81 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Investment Services's company achievement, Most analysts pointed out.

Within Investment Services industry 71 other companies have achieved higher Revenue quarter on quarter growth. While Aikido Pharma Inc's Revenue growth quarter on quarter, overall rank is 3690.


Revenue Q/Q Growth Company Ranking
Within: No.
Investment Services Industry #72
Financial Sector #796
Overall #3690
Revenue Q/Q Growth Company Ranking
Within: No.
Investment Services Industry #72
Financial Sector #796
Overall #3690
Revenue Q/Q Growth Statistics
High Average Low
1256.34 % 87.8 % -100 %
(Sep 30 2023)  


DOMH's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Aikido Pharma Inc disclosed fall in Revenue from the first quarter by -53.12% to $ 16.79 millions, from $ 35.81 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Investment Services's company achievement, Most analysts pointed out.

Within Investment Services industry 71 other companies have achieved higher Revenue quarter on quarter growth. While Aikido Pharma Inc's Revenue growth quarter on quarter, overall rank is 3690.


Aikido Pharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 133.46 $ 155.59 $ 127.02 $ 103.54 $ 56.76
Y / Y Revenue Growth (TTM) 135.14 % 547.76 % 599.99 % 722.44 % 496.9 %
Year on Year Revenue Growth Overall Ranking # 44 # 31 # 21 # 0 # 0
Seqeuential Revenue Change (TTM) -14.22 % 22.49 % 22.68 % 82.42 % 136.31 %
Seq. Revenue Growth (TTM) Overall Ranking # 146 # 417 # 230 # 0 # 189


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Aikido Pharma Inc's cumulative twelve months Revenue were $ 133 millions, company would post below average annual Revenue growth of 136.31% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Aikido Pharma Inc's Revenue growth from the 35.81% growth in Mar 31 2026.

Among companies within the Financial sector 5 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 31 to 44.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Investment Services Industry # 3
Financial Sector # 6
Overall # 44

Revenue TTM Y/Y Growth Statistics
High Average Low
691.09 %
 295.91 %
-68.3 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 16
S&P 500 # 146
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Aikido Pharma Inc's cumulative twelve months Revenue were $ 133 millions, company would post below average annual Revenue growth of -68.3% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Aikido Pharma Inc's Revenue growth from the 35.81% growth in Mar 31 2026.

Among companies within the Financial sector 5 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 31 to 44.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Investment Services Industry # 3
Financial Sector # 6
Overall # 44

Revenue TTM Y/Y Growth Statistics
High Average Low
691.09 %
295.91 %
-68.3 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 16
S&P 500 # 146




Other Revenue Growth
Investment Services Industry Revenue Growth Trends and Statistics
Financial Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DOMH's Revenue Growth Ratio versus Investment Services Industry, Financial Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Financial SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Creative Media and Community Trust Corporation-0.02%$ -0.020 millions
International Bancshares Corporation-0.02%$ -0.023 millions
First Northwest Bancorp-0.03%$ -0.030 millions
Macerich Co-0.03%$ -0.034 millions
Southstate Bank Corp-0.08%$ -0.077 millions
American International Group Inc -0.08%$ -0.085 millions
Markel Group Inc -0.10%$ -0.102 millions
Silvercrest Asset Management Group Inc -0.17%$ -0.172 millions
Cantor Fitzgerald Income Trust Inc -0.20%$ -0.202 millions
Oportun Financial Corporation-0.48%$ -0.477 millions
Lamar Advertising Co-0.54%$ -0.542 millions
Siriuspoint Ltd -0.55%$ -0.548 millions
Marketaxess Holdings Inc -0.55%$ -0.553 millions
Apple Hospitality Reit Inc -0.66%$ -0.656 millions
Weyerhaeuser Company-0.90%$ -0.902 millions
Rbb Bancorp-0.96%$ -0.960 millions
Aflac Incorporated-1.03%$ -1.034 millions
Enterprise Financial Services Corp-1.13%$ -1.125 millions
Modiv Industrial Inc -1.17%$ -1.175 millions
Galaxy Digital Inc -1.20%$ -1.203 millions
Lightstone Value Plus REIT IV, Inc.-1.23%$ -1.230 millions
Crawford and Co-1.37%$ -1.366 millions
Coastal Financial Corporation-1.49%$ -1.493 millions
California Bancorp Ca-1.59%$ -1.594 millions
Rexford Industrial Realty Inc -1.60%$ -1.604 millions
Clipper Realty Inc -1.72%$ -1.716 millions
First Northern Community Bancorp-1.74%$ -1.736 millions
Western New England Bancorp Inc -2.35%$ -2.354 millions
Donegal Group Inc -2.44%$ -2.439 millions
Choiceone Financial Services Inc -2.58%$ -2.582 millions


About Aikido Pharma Inc Revenue Growth Rates (DOMH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Dominari Holdings Inc (CIK 12239).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-026832
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Dominari Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.